Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4

J. M J Hammond, J. Hannig, D. Schwartz, Charles Williams Flexner

Research output: Contribution to journalArticle

Abstract

RBCs with transmembrane CD4 receptors have potent anti-HIV activity and can be created exvivo in the presence of an electrical field. We conducted a double-blind, randomised dose escalation study in 19 HIV-infected volunteers, to assess the safety, tolerability and anti-HIV activity of autologous RBCs modified by electroinsertion with recombinant transmembrane CD4 (rCD4) protein expressed by a baculovirus vector. Survival of 51chromium-labelled RBC-rCD4 was evaluated in 3 HIV-infected subjects. In two direct Coomb's negative subjects, mean survival t 1/2 was 32.1 and 32.4 days, and in one direct Coomb's positive subject, t 1/2 was 24.2 days. RBC-rCD4 infusion was safe and well-tolerated in all subjects, and survival kinetics of modified RBCs was similar to that of normal RBCs in healthy volunteers. RBCs can be used as carriers for recombinant proteins with therapeutic potential without affecting circulating t 1/2.

Original languageEnglish (US)
Pages (from-to)193
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997

Fingerprint

Erythrocytes
HIV
Survival
CD4 Antigens
Baculoviridae
Recombinant Proteins
Volunteers
Healthy Volunteers
Carrier Proteins
Safety
Proteins
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4. / Hammond, J. M J; Hannig, J.; Schwartz, D.; Flexner, Charles Williams.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 193.

Research output: Contribution to journalArticle

@article{9bb4e1f2d8ba4618bec00b383b207f7b,
title = "Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4",
abstract = "RBCs with transmembrane CD4 receptors have potent anti-HIV activity and can be created exvivo in the presence of an electrical field. We conducted a double-blind, randomised dose escalation study in 19 HIV-infected volunteers, to assess the safety, tolerability and anti-HIV activity of autologous RBCs modified by electroinsertion with recombinant transmembrane CD4 (rCD4) protein expressed by a baculovirus vector. Survival of 51chromium-labelled RBC-rCD4 was evaluated in 3 HIV-infected subjects. In two direct Coomb's negative subjects, mean survival t 1/2 was 32.1 and 32.4 days, and in one direct Coomb's positive subject, t 1/2 was 24.2 days. RBC-rCD4 infusion was safe and well-tolerated in all subjects, and survival kinetics of modified RBCs was similar to that of normal RBCs in healthy volunteers. RBCs can be used as carriers for recombinant proteins with therapeutic potential without affecting circulating t 1/2.",
author = "Hammond, {J. M J} and J. Hannig and D. Schwartz and Flexner, {Charles Williams}",
year = "1997",
language = "English (US)",
volume = "61",
pages = "193",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4

AU - Hammond, J. M J

AU - Hannig, J.

AU - Schwartz, D.

AU - Flexner, Charles Williams

PY - 1997

Y1 - 1997

N2 - RBCs with transmembrane CD4 receptors have potent anti-HIV activity and can be created exvivo in the presence of an electrical field. We conducted a double-blind, randomised dose escalation study in 19 HIV-infected volunteers, to assess the safety, tolerability and anti-HIV activity of autologous RBCs modified by electroinsertion with recombinant transmembrane CD4 (rCD4) protein expressed by a baculovirus vector. Survival of 51chromium-labelled RBC-rCD4 was evaluated in 3 HIV-infected subjects. In two direct Coomb's negative subjects, mean survival t 1/2 was 32.1 and 32.4 days, and in one direct Coomb's positive subject, t 1/2 was 24.2 days. RBC-rCD4 infusion was safe and well-tolerated in all subjects, and survival kinetics of modified RBCs was similar to that of normal RBCs in healthy volunteers. RBCs can be used as carriers for recombinant proteins with therapeutic potential without affecting circulating t 1/2.

AB - RBCs with transmembrane CD4 receptors have potent anti-HIV activity and can be created exvivo in the presence of an electrical field. We conducted a double-blind, randomised dose escalation study in 19 HIV-infected volunteers, to assess the safety, tolerability and anti-HIV activity of autologous RBCs modified by electroinsertion with recombinant transmembrane CD4 (rCD4) protein expressed by a baculovirus vector. Survival of 51chromium-labelled RBC-rCD4 was evaluated in 3 HIV-infected subjects. In two direct Coomb's negative subjects, mean survival t 1/2 was 32.1 and 32.4 days, and in one direct Coomb's positive subject, t 1/2 was 24.2 days. RBC-rCD4 infusion was safe and well-tolerated in all subjects, and survival kinetics of modified RBCs was similar to that of normal RBCs in healthy volunteers. RBCs can be used as carriers for recombinant proteins with therapeutic potential without affecting circulating t 1/2.

UR - http://www.scopus.com/inward/record.url?scp=33748983254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748983254&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748983254

VL - 61

SP - 193

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -